17 results about "Sclerostin" patented technology

The invention is directed to a method of treating pediatric osteogenesis imperfecta comprising administering an anti-sclerostin antibody to the subject in an amount ranging from 1 mg / kg to 10 mg / kg.

The present application provides methods of use, specifically methods of treatment of a disease, disorder, or condition (e.g, a low bone mass condition such as osteoporosis) in a human individual, comprising administration of novel bispecific antibodies that bind to both sclerostin and DKK-1 (e.g, anti-Sclerostin x anti-DKK-1 bispecific antibodies). The present application also provides methods of increasing bone mineral density in a human individual comprising administration of novel anti-Scl erostin x anti-DKK-1 bispecific antibodies. The present application further provides methods of reducing risk of bone fracture (e.g., osteoporotic fracture) in a human individual comprising administration of novel anti-Sclerostin x anti-DKK-1 bispecific antibodies.

The application belongs to the technical field of medical products and health products, and particularly relates to a compound targeting sclerostin and application thereof. A novel small-molecule compound is found and prepared, the small-molecule compound has good sclerostin binding capacity, sclerostin inhibition and the like, and can be used as a candidate drug for preventing or treating osteoporosis and bone fracture.

The invention provides an osteoprotegerin recombinant protein, a monoclonal antibody and application of the osteoprotegerin recombinant protein and the monoclonal antibody, and relates to the technical field of biological detection, and the amino acid sequence of the recombinant protein is as shown in SEQ ID No.1. The invention provides the osteoprotegerin recombinant protein, a monoclonal antibody pair with high specificity is screened on the basis of the osteoprotegerin recombinant protein, an osteoprotegerin double-antibody sandwich method is established, the osteoprotegerin protein can be specifically detected, the sensitivity is high, a simple and convenient biological detection method is provided, and the application prospect is relatively good.

The present invention belongs to the field of medicine, and specifically relates to a bone growth promoter and its application in the medical field. The present invention, for the first time, discovered through high-throughput virtual screening the inhibitory effect of morugin on the osteoblastic and osteoporosis-fighting benchmark target, sclerostin protein, and verified this through experiments. At the same time, the osteoblastic differentiation-promoting effect of morugin was confirmed for the first time through in vitro and animal experiments. The present invention proposes morugin and its pharmaceutically acceptable salts as a bone growth promoter, which can be used alone or in combination to promote bone growth and fight osteoporosis. Its product form includes medicine.

Aspects of the disclosure relate to compositions and methods for treating diseases or disorders associated with bone fracture and critical-sized bone defect. In some embodiments, the disclosure provides isolated nucleic acids and expression constructs (e.g., rAAVs, etc.) that encode one or both of the inhibitory nucleic acids targeting Schnurri 3 (SHN3) and the inhibitory nucleic acids targeting sclerostin (SOST).

The present application belongs to the field of biomedical and cosmetic technology, and particularly relates to the application of periostin in the preparation of preparations for promoting the activity of hair follicle cells or for preventing and treating alopecia. The present application first discovers that periostin has the activity of regulating hair follicle papilla cells, hair matrix cells and outer root sheath cells, can promote the proliferation of hair follicle papilla cells, hair matrix cells and outer root sheath cells, improve the hair induction ability of hair follicle papilla cells, and promote the hair follicle cycle transformation, hair growth and thickening, and can be applied to the preparation of preparations for treating alopecia.

The present application provides anti-Sclerostin constructs that bind to Sclerostin, nucleic acid molecules encoding an amino acid sequence of the anti-Sclerostin construct, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-Sclerostin construct, pharmaceutical compositions containing the anti-Sclerostin construct, and methods of using the anti-Sclerostin construct or compositions.

Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin / Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density; a method of ameliorating the effects of an osteoclast-related disorder; a method of treating a bone-related disorder by maintaining bone density; and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphosphonate is contraindicated.

The present invention relates to an antibody that specifically binds to sclerostin of SEQ ID NO: 1, characterized in that the antibody comprises a heavy chain comprising the amino acid sequence Pro-Ala-Arg-Gly (SEQ ID NO: 8) at the C-terminal end of the heavy chain, wherein the antibody comprises a light chain amino acid sequence exposed in SEQ ID NO: 12 and a heavy chain amino acid sequence exposed in SEQ ID NO: 13 or SEQ ID NO: 14.

Provided is the use of a mulberry total polyphenol extract in the preparation of a product for promoting bone formation. The active ingredients of the mulberry total polyphenol extract include phenolic acids, polyphenol derivatives, flavones, isoflavones and tannins. The product for promoting bone formation can promote osteoblast proliferation, promote osteogenic calcification, inhibit sclerostin activity, and / or promote bone growth.

Aspects of the disclosure relate to compositions and methods for modulating bone growth, for example by increasing osteogenesis and / or decreasing osteoclastogenesis. The disclosure is based, in part, on recombinant adeno-associated virus (rAAV) vectors encoding microRNAs or miRNA inhibitors that inhibit expression or activity of gene products in the WNT pathway, for example Schnurri-3 (SHN3), sclerostin (SOST), and / or dickkopf-1 (DKK-1). In some embodiments, compositions described by the disclosure are useful for treating certain bone diseases, disorders, or injuries, such as alveolar bone loss and bone fractures.

The present application relates to a kind of Romosozumab antibody stable preparation, the preparation includes the therapeutically effective dose of Romosozumab antibody or its antigen fragment, pharmaceutically acceptable cosolvent hydroxypropyl-β-cyclodextrin and surfactant polysorbate 20 and polysorbate 80, the preparation has long-term stability and good solubility.The present application also provides the preparation method of the preparation, and its use in the preparation of the drug for treating, preventing and / or improving any with anti-sclerostin related disease or symptom.

The present application relates to the technical field of biological medicine, and discloses a screening and verification method of a small-molecule inhibitor targeting a specific domain of sclerostin. The compound provided by the present application is obtained by structural modification, skeleton derivation design and molecular docking screening of a lead small-molecule compound tetrahydrofolic acid targeting the loop3 domain of sclerostin. The compound can specifically target and combine with the loop3 domain of sclerostin, can re-activate the Wnt signal inhibited by sclerostin, and restore the effect of Wnt signal in promoting bone formation. The sclerostin inhibitor containing the compound can inhibit various muscle-skeletal system diseases mediated by sclerostin activation, has wide application range and strong targeting property. Based on the characteristics that the compound targets and combines with the loop3 domain of sclerostin but not the loop2 domain, when the compound is used for preparing a drug for preventing and treating diseases mediated by sclerostin, the risk of cardiovascular diseases caused in the process of using the drug can be reduced.

The present invention relates to aptamer conjugates for targeted degradation of sclerostin, and more particularly, to aptamer conjugates for targeted degradation of sclerostin. In particular, the present invention relates to conjugates of aptamers directed to osteosclerosis proteins and ligands capable of targeting the protein degradation pathway, and uses of the conjugates for degrading osteosclerosis proteins.

Bispecific antibodies that target both human RANKL and sclerostin are provided. Also provided herein are polynucleotides encoding the bispecific antibodies, pharmaceutical compositions comprising the bispecific antibodies, and methods of producing the bispecific antibodies. Medical uses of the bispecific antibodies described herein are also disclosed.